SENTI-401
Colorectal Cancer (CRC)
PreclinicalResearch ongoing
Key Facts
About Senti Biosciences
Senti Biosciences is leveraging its proprietary Gene Circuit platform to develop a new generation of intelligent cell therapies, primarily for oncology. The company's lead candidate, SENTI-202, is in a Phase 1 trial for acute myeloid leukemia (AML) and has shown positive preliminary efficacy. Senti's strategy combines advancing its wholly-owned pipeline with exploring platform applications in other modalities and diseases through partnerships.
View full company profileTherapeutic Areas
Other Colorectal Cancer (CRC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Nadunolimab (CAN04) | Cantargia | Preclinical |